Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...

The Value and Limitations of Biopsies for Small Renal Masses - Phillip Pierorazio ...

Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...

Advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), remains one of the most challenging malignancies to treat. While androgen-deprivation therapies and next ...

It is estimated that a total of 0.9 million patients with prostate cancer would potentially require radiotherapy in the year 2024 across all income groups and would have considerable variation in ...

PSMA-PET/CT has emerged as a superior diagnostic tool for prostate cancer, demonstrating enhanced accuracy over conventional imaging methods. Although sensitive for detecting local and metastatic ...

Ultrahypofractionation presents challenges for a subset of high-risk prostate cancer patients due to the large planning target volume (PTV) margin required for the seminal vesicles. Online adaptive ...

Background: The role of molecular imaging in urothelial cancer is less defined than other cancers, and its utility remains controversial due to limitations such as high urinary tracer excretion, ...

In NCCN favorable intermediate-risk (FIR) prostate cancer (PCa) patients treated with radical prostatectomy (RP), we tested the effect of upstaging and upgrading on cancer-specific mortality (CSM).

Incidence of distant stage prostate cancer is increasing in the United States. Research is needed to understand trends by social and geographic factors. To examine trends in prostate cancer incidence ...